Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Janssen Files NDA for Anticancer Agent Ibrutinib in Japan
November 27, 2014
- Oncolys Files IND Application for Novel Cancer Treatment OBP-801 in US
November 27, 2014
- Kaken Banking on Clenafin to Boost Dermatology Biz
November 27, 2014
- Bulk Antibody Production Efficiency Up 10-fold, Production Costs Down “Several-fold” Since 2002: Chugai
November 26, 2014
- Amgen Calls Off Clinical Studies of Rilotumumab for Gastric Cancer
November 26, 2014
- MSD to Ensure Appropriate Use of Insomnia Drug Belsomra
November 26, 2014
- Eisai Launches Halaven in Brazil
November 26, 2014
- Eisai Launches Fycompa in Hong Kong
November 26, 2014
- MSD Seeks Japan Regulatory Approval for Once-Weekly DPP-4 Inhibitor
November 25, 2014
- Rushed Settlements Dragged Down Drug Delivery Prices: Vital KSK Exec
November 25, 2014
- Merck Serono Transfers Marketing Rights for Saizen to Fujifilm Pharma
November 25, 2014
- Top Two Japan Universities to Offer Undergrads Amgen-Sponsored Lab Experience Programs
November 21, 2014
- Domestic Subgroup Analysis Confirms Efficacy of Cimzia: Astellas, UCB Japan
November 21, 2014
- Kissei Files NDA for Hyperphosphatemia Treatment in Japan
November 21, 2014
- CareNet Teams Up with Indian Firm on Marketing Solutions for Drug Makers
November 20, 2014
- Ranbaxy Sues FDA for Revoking Tentative Approvals for Nexium, Valcyte Generics
November 20, 2014
- Takeda Ordered to Pay US$155,000 for Spoliation of Evidence in Actos Case
November 20, 2014
- Nipro Pharma Joins Hands with Thai Firm on Drug Distribution
November 20, 2014
- Mirena Approved for Dysmenorrhea Based on Data from Public Domain: Bayer Yakuhin
November 20, 2014
- 30% of Pharmacies Handling Blopress AGs Likely to Use Other Makers’ Generics: Survey
November 19, 2014
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…